4.7 Article

Circadian Regulator CLOCK Recruits Immune-Suppressive Microglia into the GBM Tumor Microenvironment

Journal

CANCER DISCOVERY
Volume 10, Issue 3, Pages 371-381

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-19-0400

Keywords

-

Categories

Funding

  1. Cancer Research Institute Irvington Postdoctoral Fellowship
  2. Harold C. and Mary L. Daily Endowment Fellowship
  3. Caroline Ross Endowed Fellowship
  4. Emerson Collective Award
  5. NIH [R01 CA231349, P01 CA117969, R01 CA084628]
  6. Clayton & Modesta William Cancer Research Fund
  7. Burkhart III Distinguished University Chair in Cancer Research Endowment

Ask authors/readers for more resources

Glioblastoma (GBM) is a lethal brain tumor containing a subpopulation of glioma stem cells (GSC). Pan-cancer analyses have revealed that stemness of cancer cells correlates positively with immunosuppressive pathways in many solid tumors, including GBM, prompting us to conduct a gain-of-function screen of epigenetic regulators that may influence GSC self-renewal and tumor immunity. The circadian regulator CLOCK emerged as a top hit in enhancing stem-cell self-renewal, which was amplified in about 5% of human GBM cases. CLOCK and its heterodimeric partner BMAL1 enhanced GSC self-renewal and triggered protumor immunity via transcriptional upregulation of OLFML3, a novel chemokine recruiting immune-suppressive microglia into the tumor microenvironment. In GBM models, CLOCK or OLFML3 depletion reduced intratumoral microglia density and extended overall survival. We conclude that the CLOCK-BMAL1 complex contributes to key GBM hallmarks of GSC maintenance and immunosuppression and, together with its downstream target OLFML3, represents new therapeutic targets for this disease. SIGNIFICANCE: Circadian regulator CLOCK drives GSC self-renewal and metabolism and promotes microglia infiltration through direct regulation of a novel microglia-attracting chemokine, OLFML3. CLOCK and/or OLFML3 may represent novel therapeutic targets for GBM.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available